Sanofi (NASDAQ:SNY) Sees Unusually-High Trading Volume – What’s Next?

Sanofi (NASDAQ:SNY) shares saw unusually-strong trading volume on Friday. 5,696,313 shares traded hands during mid-day trading, an increase of 67% from the average daily volume of 3,414,580 shares. The stock last traded at $44.4260 and had previously closed at $43.13.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SNY. DZ Bank restated a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. Berenberg Bank restated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. Sanford C. Bernstein reiterated a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada initiated coverage on shares of Sanofi in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and a consensus target price of $49.50.

Sanofi Trading Up 3.2%

The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The company has a market cap of $107.94 billion, a P/E ratio of 23.35, a PEG ratio of 1.30 and a beta of 0.33. The business has a fifty day moving average price of $42.22 and a 200-day moving average price of $44.37.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.24 EPS. On average, analysts forecast that Sanofi will post 5.00 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC grew its stake in shares of Sanofi by 21.5% during the second quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after buying an additional 29,283 shares during the last quarter. Archford Capital Strategies LLC acquired a new stake in Sanofi during the 2nd quarter valued at approximately $1,417,000. Assetmark Inc. lifted its holdings in Sanofi by 14.8% in the first quarter. Assetmark Inc. now owns 509,464 shares of the company’s stock valued at $24,546,000 after buying an additional 65,796 shares during the period. AMG National Trust Bank bought a new stake in shares of Sanofi during the 1st quarter valued at about $2,719,000. Finally, Manning & Napier Advisors LLC grew its position in shares of Sanofi by 728,134.8% during the 1st quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after buying an additional 1,194,141 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.